FDA announced the availability of draft guidance for the conduct of in vivo absorption trials, and describes a methodology that adapts “maximal usage trial” (MUsT) principles for topical active ingredients that are under consideration for inclusion in an OTC drug monograph. The guidance includes discussions about how to study the topical active ingredient’s effects on specific subgroups of vulnerable patients like children and the elderly.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
